key: cord-0732206-g1l17pqw
authors: Fissel, John A.; Mestas, Javier; Chen, Pei Ying; Flores-Vazquez, Jessica; Truong, Thao T.; Bootwalla, Moiz; Maglinte, Dennis T.; Gai, Xiaowu; Dien Bard, Jennifer
title: Implementation of a Streamlined SARS-CoV-2 Whole-Genome Sequencing Assay for Expeditious Surveillance during the Emergence of the Omicron Variant
date: 2022-03-23
journal: J Clin Microbiol
DOI: 10.1128/jcm.02569-21
sha: 276ac222cd3584df32afa983637796f24ce9c258
doc_id: 732206
cord_uid: g1l17pqw

nan

Following implementation, all clinical specimens positive for SARS-CoV-2 by RT-PCR with sufficient viral titer (cycle threshold (Ct) ,30) are automatically reflexed to WGS. Samples were batched into full runs of 14 patient samples plus 2 controls, twice weekly, to allow for turnaround time (TAT) range of 24-96 h. While the Ampliseq assay has about half the throughput of the CleanPlex assay on a weekly basis, it requires less than a tenth of the hands-on time ( Table 2) . Weekly testing throughput quickly expanded as we transitioned to Monday-Friday testing once a case of S-gene dropout detected by the TaqPath COVID-19 RT-PCR assay suspicious for the omicron variant (lineage B.1.1.529) was identified in December 2021. The automated features of the Ion Torrent Genexus system allowed us to quickly reflex to SARS-CoV-2 WGS. Within 30 h of initial SARS-CoV-2 detection by RT-PCR, the omicron variant was reported in the EMR. The analysis was significantly simplified through software plugins, which automatically list mutations and produce SARS-CoV-2 variant calls ( Table 2) . The time to genotyping result was approximately 44 h from the time specimen was received by the laboratory. Such rapid TATs can facilitate clinically actionable results, enabling critical outbreak investigations and therapeutic management within days rather than weeks. Since implementation, the genomic epidemiology has rapidly transitioned to omicron predominance (Fig. 1) .

The system currently has some limitations. The throughput is only 16 samples per run for this assay, including any controls. There is potential for reagent waste if processing less than 16 samples per run, as one of four lanes of the Genexus chip is consumed for each automated run. When the omicron case was discovered, the throughput was sufficient as SARS-CoV-2 positivity at our institution was 5.47%, but as case positivity increases, the resulting backlog could increase TATs or require prioritization of samples. On the other hand, the low throughput may be more beneficial in some laboratories. There is also the flexibility to increase throughput by switching to manual library prep. While this does increase the wet lab hands-on time, it still takes advantage of the automated analysis. Sequencing data quality is reduced when loading mixed viral titer samples onto the instrument in the same run but can be improved by batching samples of similar titers together. Overall, this methodology provides a significantly simplified workflow that makes it possible to generate real-time in-house WGS results and allows for a routine clinical laboratory to pursue genomic surveillance. These technological advances could have lasting benefit by offering clinical microbiology laboratories realistic tools to explore other infectious diseases NGS assays, from genotyping other viruses for the purposes of detecting resistance markers to inform antiviral therapy to identification of bacterial and fungal pathogens from clinical specimens.

Clinical and infection prevention applications of severe acute respiratory syndrome coronavirus 2 genotyping: an Infectious Diseases Society of America/American Society for Microbiology consensus review document

Utility of viral whole-genome sequencing for institutional infection surveillance during the coronavirus disease 2019 (COVID-19) pandemic

Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study

Genomic and healthcare dynamics of nosocomial SARS-CoV-2 transmission

Finding the middle ground with the clinical laboratory's role in SARS-CoV-2 genomic surveillance

Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation

Whole-genome sequencing of SARS-CoV-2: assessment of the Ion Torrent AmpliSeq panel and comparison with the Illumina MiSeq ARTIC Protocol

Association of Public Health Laboratories (APHL). 2021. Recommendations for SARS-CoV-2 sequence data quality & reporting

SARS-CoV-2 variant classifications and definitions

FIG 1 Number of cases of delta and omicron variants that were sequenced at our institution during the month of